SA34 Real-World Treatment Outcomes Among Relapsed/Refractory Patients with Mantle Cell Lymphoma Treated with Ibrutinib or Acalabrutinib
Jun 1, 2023, 00:00 AM
10.1016/j.jval.2023.03.2250
https://www.valueinhealthjournal.com/article/S1098-3015(23)02350-1/fulltext
Section Title :
Section Order :
11571
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)02350-1&doi=10.1016/j.jval.2023.03.2250